I Thirkettle1, P Harvey, P S Hasleton, R Y Ball, R M Warn. 1. Department of Histopathology/Cytopathology, Norfolk & Norwich Hospital, School of Biological Sciences, University of East Anglia, UK.
Abstract
AIMS: To assess the immunoreactivity of malignant mesotheliomas for N- and E-cadherins, hepatocyte growth factor/scatter factor (HGF/SF) and the tyrosine kinase receptors, met and erbB-2. METHODS AND RESULTS: Pleural malignant mesotheliomas were stained using a standard indirect immunoperoxidase method applied to paraffin sections. Malignant mesotheliomas were immunoreactive for N-cadherin (26/29; 90%), met (29/29; 100%) and erbB-2 (28/29; 97%). Focal immunoreactivity was present for E-cadherin in epithelioid or mixed tumours (14/25; 56%), and for HGF/SF (9/24; 38%). CONCLUSIONS: Expression of N-cadherin supports the diagnosis of malignant mesothelioma and use of appropriate antibodies would be a useful addition to a diagnostic antibody panel. Focal staining for E-cadherin does not exclude mesothelioma. Signalling pathways mediated via met and erbB-2 may play a role in the growth and spread of malignant mesotheliomas.
AIMS: To assess the immunoreactivity of malignant mesotheliomas for N- and E-cadherins, hepatocyte growth factor/scatter factor (HGF/SF) and the tyrosine kinase receptors, met and erbB-2. METHODS AND RESULTS:Pleural malignant mesotheliomas were stained using a standard indirect immunoperoxidase method applied to paraffin sections. Malignant mesotheliomas were immunoreactive for N-cadherin (26/29; 90%), met (29/29; 100%) and erbB-2 (28/29; 97%). Focal immunoreactivity was present for E-cadherin in epithelioid or mixed tumours (14/25; 56%), and for HGF/SF (9/24; 38%). CONCLUSIONS: Expression of N-cadherin supports the diagnosis of malignant mesothelioma and use of appropriate antibodies would be a useful addition to a diagnostic antibody panel. Focal staining for E-cadherin does not exclude mesothelioma. Signalling pathways mediated via met and erbB-2 may play a role in the growth and spread of malignant mesotheliomas.
Authors: Gavin J Gordon; Graham N Rockwell; Roderick V Jensen; James G Rheinwald; Jonathan N Glickman; Joshua P Aronson; Brian J Pottorf; Matthew D Nitz; William G Richards; David J Sugarbaker; Raphael Bueno Journal: Am J Pathol Date: 2005-06 Impact factor: 4.307
Authors: P Cacciotti; R Libener; P Betta; F Martini; C Porta; A Procopio; L Strizzi; L Penengo; M Tognon; L Mutti; G Gaudino Journal: Proc Natl Acad Sci U S A Date: 2001-09-25 Impact factor: 11.205
Authors: Maria E Ramos-Nino; Steven R Blumen; Tara Sabo-Attwood; Harvey Pass; Michele Carbone; Joseph R Testa; Deborah A Altomare; Brooke T Mossman Journal: Am J Respir Cell Mol Biol Date: 2007-09-13 Impact factor: 6.914
Authors: Foteini Economidou; George Margaritopoulos; Katerina M Antoniou; Nikolaos M Siafakas Journal: Exp Ther Med Date: 2010-01-01 Impact factor: 2.447
Authors: Felix Bremmer; Bernhard Hemmerlein; Arne Strauss; Peter Burfeind; Paul Thelen; Heinz-Joachim Radzun; Carl Ludwig Behnes Journal: BMC Clin Pathol Date: 2012-10-15